Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 99

1.

Oncolytic virotherapy as emerging immunotherapeutic modality: potential of parvovirus h-1.

Moehler M, Goepfert K, Heinrich B, Breitbach CJ, Delic M, Galle PR, Rommelaere J.

Front Oncol. 2014 May 1;4:92. doi: 10.3389/fonc.2014.00092. eCollection 2014. Review.

PMID:
24822170
[PubMed]
Free PMC Article
2.

Activation of the human immune system by chemotherapeutic or targeted agents combined with the oncolytic parvovirus H-1.

Moehler M, Sieben M, Roth S, Springsguth F, Leuchs B, Zeidler M, Dinsart C, Rommelaere J, Galle PR.

BMC Cancer. 2011 Oct 26;11:464. doi: 10.1186/1471-2407-11-464.

PMID:
22029859
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Complementary induction of immunogenic cell death by oncolytic parvovirus H-1PV and gemcitabine in pancreatic cancer.

Angelova AL, Grekova SP, Heller A, Kuhlmann O, Soyka E, Giese T, Aprahamian M, Bour G, Rüffer S, Cziepluch C, Daeffler L, Rommelaere J, Werner J, Raykov Z, Giese NA.

J Virol. 2014 May;88(10):5263-76. doi: 10.1128/JVI.03688-13. Epub 2014 Feb 26.

PMID:
24574398
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Activation of the human immune system via toll-like receptors by the oncolytic parvovirus H-1.

Sieben M, Schäfer P, Dinsart C, Galle PR, Moehler M.

Int J Cancer. 2013 Jun 1;132(11):2548-56. doi: 10.1002/ijc.27938. Epub 2012 Nov 29.

PMID:
23151948
[PubMed - indexed for MEDLINE]
Free Article
5.

Combined oncolytic and vaccination activities of parvovirus H-1 in a metastatic tumor model.

Raykov Z, Grekova S, Galabov AS, Balboni G, Koch U, Aprahamian M, Rommelaere J.

Oncol Rep. 2007 Jun;17(6):1493-9.

PMID:
17487410
[PubMed - indexed for MEDLINE]
6.

NK-cell-dependent killing of colon carcinoma cells is mediated by natural cytotoxicity receptors (NCRs) and stimulated by parvovirus infection of target cells.

Bhat R, Rommelaere J.

BMC Cancer. 2013 Jul 31;13:367. doi: 10.1186/1471-2407-13-367.

PMID:
23902851
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Therapeutic implications of the enhanced short and long-term cytotoxicity of radiation treatment followed by oncolytic parvovirus H-1 infection in high-grade glioma cells.

Geletneky K, Hartkopf AD, Krempien R, Rommelaere J, Schlehofer JR.

Bioeng Bugs. 2010 Nov-Dec;1(6):429-33. doi: 10.4161/bbug.1.6.12943.

PMID:
21468212
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Influence of the oncolytic parvovirus H-1, CTLA-4 antibody tremelimumab and cytostatic drugs on the human immune system in a human in vitro model of colorectal cancer cells.

Heinrich B, Goepfert K, Delic M, Galle PR, Moehler M.

Onco Targets Ther. 2013 Aug 20;6:1119-27. doi: 10.2147/OTT.S49371. eCollection 2013.

PMID:
23986643
[PubMed]
Free PMC Article
9.

Interferon γ improves the vaccination potential of oncolytic parvovirus H-1PV for the treatment of peritoneal carcinomatosis in pancreatic cancer.

Grekova SP, Aprahamian M, Daeffler L, Leuchs B, Angelova A, Giese T, Galabov A, Heller A, Giese NA, Rommelaere J, Raykov Z.

Cancer Biol Ther. 2011 Nov 15;12(10):888-95. doi: 10.4161/cbt.12.10.17678. Epub 2011 Nov 15.

PMID:
22024742
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Enhancement of NK cell antitumor responses using an oncolytic parvovirus.

Bhat R, Dempe S, Dinsart C, Rommelaere J.

Int J Cancer. 2011 Feb 15;128(4):908-19. doi: 10.1002/ijc.25415.

PMID:
20473905
[PubMed - indexed for MEDLINE]
11.

Antitumoral immune response by recruitment and expansion of dendritic cells in tumors infected with telomerase-dependent oncolytic viruses.

Edukulla R, Woller N, Mundt B, Knocke S, Gürlevik E, Saborowski M, Malek N, Manns MP, Wirth T, Kühnel F, Kubicka S.

Cancer Res. 2009 Feb 15;69(4):1448-58. doi: 10.1158/0008-5472.CAN-08-1160. Epub 2009 Feb 3. Erratum in: Cancer Res. 2011 Mar 1;71(5):2021. Ramakrishna, Edukulla [corrected to Edukulla, Ramakrishna].

PMID:
19190348
[PubMed - indexed for MEDLINE]
Free Article
12.

Regression of advanced rat and human gliomas by local or systemic treatment with oncolytic parvovirus H-1 in rat models.

Geletneky K, Kiprianova I, Ayache A, Koch R, Herrero Y Calle M, Deleu L, Sommer C, Thomas N, Rommelaere J, Schlehofer JR.

Neuro Oncol. 2010 Aug;12(8):804-14. doi: 10.1093/neuonc/noq023. Epub 2010 Mar 18.

PMID:
20299703
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Oncolytic virotherapy.

Russell SJ, Peng KW, Bell JC.

Nat Biotechnol. 2012 Jul 10;30(7):658-70. doi: 10.1038/nbt.2287. Review.

PMID:
22781695
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Phase I/IIa study of intratumoral/intracerebral or intravenous/intracerebral administration of Parvovirus H-1 (ParvOryx) in patients with progressive primary or recurrent glioblastoma multiforme: ParvOryx01 protocol.

Geletneky K, Huesing J, Rommelaere J, Schlehofer JR, Leuchs B, Dahm M, Krebs O, von Knebel Doeberitz M, Huber B, Hajda J.

BMC Cancer. 2012 Mar 21;12:99. doi: 10.1186/1471-2407-12-99.

PMID:
22436661
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Parvovirus H-1-induced tumor cell death enhances human immune response in vitro via increased phagocytosis, maturation, and cross-presentation by dendritic cells.

Moehler MH, Zeidler M, Wilsberg V, Cornelis JJ, Woelfel T, Rommelaere J, Galle PR, Heike M.

Hum Gene Ther. 2005 Aug;16(8):996-1005.

PMID:
16076257
[PubMed - indexed for MEDLINE]
16.

Immune cells participate in the oncosuppressive activity of parvovirus H-1PV and are activated as a result of their abortive infection with this agent.

Grekova S, Aprahamian M, Giese N, Schmitt S, Giese T, Falk CS, Daeffler L, Cziepluch C, Rommelaere J, Raykov Z.

Cancer Biol Ther. 2010 Dec 15;10(12):1280-9. Epub 2010 Dec 15.

PMID:
21124075
[PubMed - indexed for MEDLINE]
Free Article
17.

Oncolytic parvoviruses as cancer therapeutics.

Rommelaere J, Geletneky K, Angelova AL, Daeffler L, Dinsart C, Kiprianova I, Schlehofer JR, Raykov Z.

Cytokine Growth Factor Rev. 2010 Apr-Jun;21(2-3):185-95. doi: 10.1016/j.cytogfr.2010.02.011. Epub 2010 Mar 7. Review.

PMID:
20211577
[PubMed - indexed for MEDLINE]
18.

Oncolytic herpes simplex virus 1 encoding 15-prostaglandin dehydrogenase mitigates immune suppression and reduces ectopic primary and metastatic breast cancer in mice.

Walker JD, Sehgal I, Kousoulas KG.

J Virol. 2011 Jul;85(14):7363-71. doi: 10.1128/JVI.00098-11. Epub 2011 May 4.

PMID:
21543507
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Oncolytic rat parvovirus H-1PV, a candidate for the treatment of human lymphoma: In vitro and in vivo studies.

Angelova AL, Aprahamian M, Balboni G, Delecluse HJ, Feederle R, Kiprianova I, Grekova SP, Galabov AS, Witzens-Harig M, Ho AD, Rommelaere J, Raykov Z.

Mol Ther. 2009 Jul;17(7):1164-72. doi: 10.1038/mt.2009.78. Epub 2009 Apr 14.

PMID:
19367260
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Modulation of viability and maturation of human monocyte-derived dendritic cells by oncolytic adenoviruses.

Schierer S, Hesse A, Müller I, Kämpgen E, Curiel DT, Schuler G, Steinkasserer A, Nettelbeck DM.

Int J Cancer. 2008 Jan 1;122(1):219-29.

PMID:
17764070
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk